Recent Announcements

Phase 3 Trial Aims to Establish Non-Motor Improvement in Parkinson’s

July 14, 2020, Salt Lake City, UT— PhotoPharmics, a pioneer in specialized phototherapy for neurodegenerative diseases, today announced a collaboration with the Center for Health + Technology (CHeT) at the University of Rochester Medical Center to conduct an at home, telemedicine, phase 3 trial to establish safety and efficacy for the company’s non-invasive specialized phototherapy device for Parkinson’s disease.

read more

Media Contact

Brett Walker


Additional News


People with Parkinson’s discuss ways they cope with their disease

PhotoPharmics recently learned the depth and breadth of ways people with Parkinson’s cope with the devastating disease when they asked a large group of them a simple question: What do you do to take your mind of Parkinson’s disease? Read more >

Survey reveals Parkinson’s disease non-motor symptoms manifest first

Parkinson’s disease is best recognized by its motor symptoms—namely tremor. But it surprised our research team, and it may surprise you as well, to learn that 87 percent of people with Parkinson’s surveyed said they noticed non-motor symptoms first; and 78 percent said they noticed non-motor symptoms even before they were formally diagnosed with Parkinson’s. Read more >

In the News

PhotoPharmics: Shining a Light on Parkinson’s Disease With a Breakthrough Device

The company is developing the first light-based, at-home device used as an add-on Parkinson’s disease therapy to receive a 510(k) de novo classification and Breakthrough Device designation from FDA. Importantly in light of the COVID-19 pandemic, its upcoming Phase III trial will be remote, and then the next hurdle will be EU MDR. Read more >

Social Media Activity


It's the week to #givethanks. We are so grateful for the many scientists, researchers and medical professionals who are working on solutions for people with Parkinson's. Thank you for your excellent work! #thanksgiving #thankful

GET TO KNOW PHOTOPHARMICS: Our prescription device is intended as an adjunct therapy for the treatment of #Parkinsonsdisease. It is intended to be used concurrently with standard dopaminergic therapy and is designed primarily for home use. Learn more at